ICON Plc (ICLR):企業の財務・戦略的SWOT分析

◆英語タイトル:ICON Plc (ICLR) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH8733FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

ICON Plc (ICLR) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ICON plc (ICON) is a contract research organization (CRO) that provides outsourced development services to the biotechnology, pharmaceutical and medical device industries worldwide. It provides specialized services that span the entire lifecycle of product development. The company’s service portfolio includes adaptive trials, biosimilars, clinical research services, commercialization and outcomes, consulting, functional services provision, medical imaging, laboratory services, resourcing solutions and strategic support and tactical solutions for traditional, in vitro diagnostic and software devices. The company offers research services in areas of cancer, genomics, central nervous system, cardiovascular, endocrine and metabolic disorders, gastrointestinal, medical device, nonalcoholic steatohepatitis (NASH), ophthalmology, rare and orphan diseases, transplant and immunology, vaccines and women’s health therapeutics areas among others. ICON is headquartered in Dublin, Ireland.

ICON Plc Key Recent Developments

Feb 24,2021: Ireland’s ICON signs agreement to acquire PRA Health Sciences
Oct 21,2020: Icon reports third quarter 2020 results
Oct 19,2020: BARDA reselects ICON as preferred partner to help strengthen US emergency preparedness and response
Oct 07,2020: ICON wins best CRO at the vaccine industry excellence wwards
Sep 03,2020: ICON launches Accellacare a global clinical research network focused on increasing patient recruitment with a patient centric approach

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
ICON Plc – Key Facts
ICON Plc – Key Employees
ICON Plc – Key Employee Biographies
ICON Plc – Major Products and Services
ICON Plc – History
ICON Plc – Company Statement
ICON Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
ICON Plc – Business Description
Geographical Segment: Ireland
Performance
Geographical Segment: Other
Performance
Geographical Segment: Rest of Europe
Performance
Geographical Segment: US
Performance
ICON Plc – Corporate Strategy
ICON Plc – SWOT Analysis
SWOT Analysis – Overview
ICON Plc – Strengths
ICON Plc – Weaknesses
ICON Plc – Opportunities
ICON Plc – Threats
ICON Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
ICON Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
ICON Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
ICON Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Oct 21, 2020: Icon reports third quarter 2020 results
Oct 19, 2020: BARDA reselects ICON as preferred partner to help strengthen US emergency preparedness and response
Oct 07, 2020: ICON wins best CRO at the vaccine industry excellence wwards
Sep 03, 2020: ICON launches Accellacare a global clinical research network focused on increasing patient recruitment with a patient centric approach
Jul 22, 2020: ICON reports second qquarter 2020 results
May 05, 2020: ICON appoints new Chief Medical Officer
Apr 22, 2020: ICON reports first quarter 2020 results
Apr 09, 2020: ICON wins multiple categories in 2020 CRO Leadership Awards third year in a row
Apr 03, 2020: ICON signs new service agreement with Pfizer
Mar 23, 2020: ICON launches the coronavirus observatory
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
ICON Plc, Key Facts
ICON Plc, Key Employees
ICON Plc, Key Employee Biographies
ICON Plc, Major Products and Services
ICON Plc, History
ICON Plc, Subsidiaries
ICON Plc, Key Competitors
ICON Plc, Ratios based on current share price
ICON Plc, Annual Ratios
ICON Plc, Annual Ratios (Cont...1)
ICON Plc, Annual Ratios (Cont...2)
ICON Plc, Interim Ratios
ICON Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
ICON Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
ICON Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[ICON Plc (ICLR):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Fluidra, S.A. (FDR):企業の財務・戦略的SWOT分析
    Fluidra, S.A. (FDR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • The Broad Institute Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary The Broad Institute Inc (Broad Institute), a subsidiary of The Broad Foundation is a non-profit research organization that conducts genomic research for treatment of human diseases. The organization transforms medicine by utilizing systematic approaches in biological sciences, to speed up th …
  • Promigas SA ESP (PROMIGAS):企業の財務・戦略的SWOT分析
    Promigas SA ESP (PROMIGAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • gel-e Inc-医療機器分野:企業M&A・提携分析
    Summary gel-e Inc (gel-e), formerly Remedium Technologies Inc is a medical device company that offers products for the treatment of acute wounds. The company's products include spray foams, bandages, gels, films, and band-aids. It offers proprietary technology platform that helps in development of w …
  • Bank Hapoalim BM:企業の戦略・SWOT・財務情報
    Bank Hapoalim BM - Strategy, SWOT and Corporate Finance Report Summary Bank Hapoalim BM - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Saudi Industrial Export Company (4140):企業の財務・戦略的SWOT分析
    Summary Saudi Industrial Export Company (SIEC) is a chemical providing company that imports, exports and sales specialty chemicals, fertilizers, industrial materials and commodities. The company's fertilizers include diammonium phosphate, sulphur, urea, triple super phosphate, granular triple super …
  • GenomicTree Co Ltd (228760):企業の製品パイプライン分析
    Summary GenomicTree Co Ltd (GenomicTree) is a medical device company that develops and commercializes diagnostic products for the screening and diagnosis of cancer. The company also provides non-invasive cancer molecular diagnostic product. Its products are used in the detection of colorectal, lung …
  • Zoll Medical Corporation:企業の戦略的SWOT分析
    Zoll Medical Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Interstate Hotels & Resorts Inc:戦略・SWOT・企業財務分析
    Interstate Hotels & Resorts Inc - Strategy, SWOT and Corporate Finance Report Summary Interstate Hotels & Resorts Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Sunquest Information Systems Inc:企業の戦略的SWOT分析
    Sunquest Information Systems Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • FANUC CORPORATION:企業の戦略・SWOT・財務情報
    FANUC CORPORATION - Strategy, SWOT and Corporate Finance Report Summary FANUC CORPORATION - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Minerals Technologies Inc (MTX):企業の財務・戦略的SWOT分析
    Minerals Technologies Inc (MTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Wells Fargo Private Bank:企業の戦略・SWOT・財務情報
    Wells Fargo Private Bank - Strategy, SWOT and Corporate Finance Report Summary Wells Fargo Private Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Dyadic International Inc (DYAI):企業の財務・戦略的SWOT分析
    Summary Dyadic International Inc (Dyadic) is a biotechnology company that develops gene expression platform for production of industrial enzymes and other proteins. The company utilizes C1 technology, an expression system based on the fungus Myceliophthora thermophila, to discover and manufacture bi …
  • Molecular Partners AG (MOLN):企業の財務・戦略的SWOT分析
    Summary Molecular Partners AG (Molecular Partners) is a clinical stage bio pharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein based anti-angiogenic drug developed for diabetic macular edema an …
  • Enanta Pharmaceuticals Inc (ENTA):企業の財務・戦略的SWOT分析
    Summary Enanta Pharmaceuticals Inc (Enanta) is a biotechnology company that discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of …
  • Guangzhou Institute of Biomedicine and Health:製薬・医療:M&Aディール及び事業提携情報
    Summary Guangzhou Institute of Biomedicine and Health (GIBH) is a research institute that develops protocols for disease control and prevention. The institute conducts research in the areas of stem cell and regenerative medicine, chemical biology, immunology and infectious diseases, public health, a …
  • Tesla Energy Operations Inc:企業の戦略的SWOT分析
    Tesla Energy Operations Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Axelar AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Axelar AB (Axelar) is a drug development company that develops various novel anti-cancer treatments. The company lead drug candidateAXL1717 is used for the treatmentof non-small cell lung cancer. It also offers treatments for disease such as glioblastoma, sarcoma, malignant melanoma and mult …
  • Web.com Group, Inc.:企業の戦略的SWOT分析
    Web.com Group, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆